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Osteoarthritis (OA) continues to affect the quality of life for over 30 million Americans.1 
This disease process can affect many different joints in the body, limiting motion and 
participation in occupational or social events and potentially causing debilitating pain. The only 
definitive treatment for OA, seemingly, is to surgically replace the affected joint(s). There are 
many in the medical field who have sought an alternative treatment to either slow the disease 
progression or mitigate symptoms from OA, which is preferable when compared to total 
arthroplasty. 
Early in the disease process, OA can cause unpleasant symptoms and begin to affect 
patients’ lives, limiting their work and preventing them from participating in various activities of 
daily living (ADLs). People often turn to over the counter (OTC) medications, like Non- 
Steroidal Anti-Inflammatory Drugs (NSAIDs) to control the pain they experience, which can 
have unfavorable effects on the body from chronic use. There is a desire for less-damaging 
alternatives to alleviate pain and improve function for patients living with OA. The standard 
approach to treating OA is to reduce overall weight, avoid aggravating movements, apply ice, 
administer NSAIDs and utilize an appropriate physical therapy treatment plan.1 These 
conservative methods should be exhausted before exploring other options, such as opioid 
prescriptions, pain management referrals and, finally, a referral for total joint replacement. 
Knees are among the most common joints affected by OA. These joints undergo an 
exponential load with even the most common tasks of ADLs, like descending stairs. Knees 
absorb a large amount of force and distribute this during movements of landing harshly, lunging 
to grab something, jogging, and lifting various objects. People in America are not typically 
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trained at an early age to properly navigate these movements for the sake of their knees and back, 
leading to improper distribution of force and ultimately leading to the progression of OA. 
There are many factors that contribute to the onset of OA in individuals that are 
sometimes either preventable or would ultimately delay the degradation of the articular cartilage 
and narrowing of joint space. The “Q Angle” can change, affecting a patient’s kinematic chain, 
putting the impact of the knee joint into an unfavorable position for optimal distribution of force 
on the articular cartilage. This negative change in Q Angle typically affects the joints above and 
below the knee, which will ultimately lead to a subsequent onset of joint pain or ultimately 
degenerate into OA. One’s occupation can greatly contribute to the overuse of the knee joints, 
increasing daily demand over many years and degrading the articular cartilage along with 
narrowing the joint space. Genetics may play an important role in contributing to the declination 
of knee articular cartilage, independent of chronic overuse. 
The mechanism of OA degradation stems from mechanical loading and increased 
presence of proinflammatory cytokines: IL-1, TNF Alpha, nitric oxide, matrix 
metalloproteinases, aggrecanases, and prostaglandins.2 Other factors contributing to knee joint 
OA are the absence or limited presence of growth factors (GF), collagens, proteoglycans, and 
anti-inflammatory cytokines (IL-4, IL-10).2 NSAIDs would primarily work by eliminating only 
one harmful subset of cytokines, prostaglandins. This, along with other conservative treatments, 
limits the effectiveness and longevity of relief from pain and improvement of function. 
Platelet-Rich Plasma (PRP) aims to mitigate symptoms and restore functionality to the 
knee joint(s) by decreasing the presence of proinflammatory cytokines and increasing the 
proliferation and genesis of the anti-inflammatory, growth promoting factors listed above. 
Platelets contain these anti-inflammatory cytokines and growth factors, which will allow for 
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stimulation of cellular growth, angiogenesis, regeneration of tissue and synthesis of new 
collagen.2 By concentrating the amount of injectable platelets, this maximizes the potential for 
optimal relief of symptomatic OA and, ideally, the regeneration of the dissipated cartilage. 
Health care providers strive to avoid referring patients with knee OA to surgery due to 
the inherent risks, the arduous task of regaining acceptable functionality, potential loss of their 
range-of-motion (ROM), unforeseen sequalae, potentially unfavorable fragility of the patient, 
and the limited lifespan of the traditional knee arthroplasty. Artificial knee joint replacements 
typically last approximately ten years, which may also be shortened with patients who are more 
active than their counterparts. The need to manage symptoms and slow the progression of OA 
with alternative means is in great demand, especially treatments which have high efficacy for 
longer durations. 
One of those alternatives is injecting corticosteroids (CS) within the affected knee joint(s) 
to decrease the inflammation and ultimately decrease the swelling and pain. This approach is 
common in medical practices but has its pitfalls. CS can relieve pain and provide people greater 
function and ROM temporarily, but this will not typically last more than several weeks to 
months, which requires patients to return often in order to regain this level of relief. The standard 
interval of CS injections ranges from every three to six months, which comes at great cost to the 
patient if they have substantial co-pays or exceed the allotted amount of coverage by their 
respective health care insurance. Chronic use of CS injections will have adverse effects, 
primarily on tissue degradation and heightened blood glucose levels caused by chronic use.3 
Hyaluronic Acid (HA) is another accepted treatment for knee OA, creating synthetic 
cross-fiber links in the articular cartilage and subtly strengthening the hyaline cartilage in the 
knee joint.4 There does not appear to be common adverse effects from the continued use of HA, 
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but it does require intra-articular injections to be administered frequently. The lack of efficacy 
from HA treatments dissuaded the medical community from establishing these injections as the 
gold standard of care.4 
Platelet-Rich Plasma (PRP) has emerged as a promising treatment of OA, particularly in 
large joints. For the treatment of knee OA PRP is non-inferior to the traditional methods, in 
improving function, pain, and ADLs. PRP is promising due to its autologous nature and appeal 
with the ever-increasing push for holistic or “natural” options in therapeutics. The patient will 
utilize properties of their own body to bolster an anti-inflammatory response and potentially 
improve the function of the knee cartilage.3 Although it requires fluid collection from a patient 
and processing which may be slightly time intensive, it offers an alternative to synthetic and 
potentially harmful traditional interventions in CS and HA injections. 
EFFECTIVENESS OF PRP 
To utilize PRP, the evidence must demonstrate that the treatment is a non-inferior choice, 
compared to HA and CS. The measure of effectiveness is primarily based on scores that are 
either subjective, or an attempt to convert subjective symptoms (i.e. pain) into objective values. 
These scoring systems quantify questionnaires or standardized written measurements into data 
points, allowing researchers to provide adequate analysis of each therapy’s efficacy. Although 
there are many different concentrations, injection intervals, variable injection sites and length of 
time studied, the overall effectiveness will be outlined in this section and the variables of 
application will be addressed in the discussion. 
In a study by Duymus et al., researchers examined the efficacy of treatment between 
PRP, HA and Ozone gas. The researchers observed an initial improvement of symptoms in the 
first month from Ozone gas, PRP and HA. The Ozone gas therapy did not significantly alleviate 
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pain or improve function past the first month. HA and PRP did not have any significant 
statistical differences at any of the evaluations within the first six-month period. However, the 
PRP group improved across both Visual Analog Scale (VAS) and Western Ontario & McMaster 
Universities Osteoarthritis Index (WOMAC) scores, compared to the HA treatment cohort. The 
VAS score is a subjective measurement for a patient’s pain rating. WOMAC is a tool used to 
assess pain, stiffness and functionality in patients with OA. These results led the authors to 
believe that PRP is a superior treatment option for mild-moderate knee OA, when compared to 
HA and Ozone gas therapies.5 
Unlike the Duymus study, an Italian study found that PRP and HA only improved knee 
OA symptoms slightly.6 This study was submitted and accepted by the American Journal of 
Sports Medicine in 2015, and provided evidence that PRP IAI’s Intra-Articular Injections (IAI) 
did not show superiority when compared to viscosupplementation.6 Filardo and colleagues 
utilized a plethora of measurement tools to directly compare each therapy. The double-blinded 
randomized-control trial showed evidence that both PRP and HA slightly improved effectiveness 
in improving knee functional status and decreased the severity of all patients’ symptoms. 
However, the researchers did not feel either treatment yielded a significant clinical or statistical 
improvement to recommend either for therapeutic use.6 
Subjective measurements alone are, seemingly, tools that can only provide limited data 
for PRP treatment. In a 2016 study out of Rush University Medical Center, researchers measured 
the effectiveness of PRP and HA via biochemical marker concentrations as an additional 
measurement to standardized subjective scoring systems. PRP application demonstrated 
improved scores throughout the duration of the study, for the subjective questionnaires. 
However, there was a considerable decrease in synovial proinflammatory cytokines after one 
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year of PRP treatments. The researchers argued the reduction in concentration of these cytokines, 
from PRP therapy, likely contributed to the improvement of function and relief of pain 
symptoms in these patients.7 
PRP demonstrated not only non-inferiority to conventional viscosupplementation, but 
also superiority to HA in the Duymus and Cole studies. These findings suggest that PRP 
treatment is a viable means to managing knee OA pathologies. However, the Filardo researchers 
observed minimal improvement and did not recommend either PRP or HA for management of 
knee OA. The data from this research demonstrates PRP’s effectiveness compared to 
conventional therapy. 
PRP EFFECTIVENESS ON DIFFERENT GRADES OF OA 
It is generally accepted that treating knee OA earlier on and with a younger patient tends 
to have better outcome potential. How far along someone is in the disease process can have 
implications for their prognosis and influence management. The Kellgren-Lawrence system for 
classification of osteoarthritis of the knee, commonly used in OA research, is graded from 
doubtful (1) to severe (4). Jubert et al performed a study on geriatric patients with severe knee 
OA (Grade 4), comparing PRP to CS injection therapies. This team discovered there was not any 
significant difference in the effectiveness of both treatments after six months.8 Although not 
statistically significant, this provides mounting evidence for the non-inferiority of PRP utilization 
when compared to CS therapy.8 Gormeli and colleagues suggest that treating patients with Grade 
4 OA is not beneficial and does not improve symptoms or composition of cartilaginous tissue.3 
EFFECTIVENESS OF PRP ON DIFFERENT AGE GROUPS 
As people age, there tends to be a global diminished response to injury and ultimately 
healing. The effects of knee OA over time will continue to deteriorate the already affected 
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articular cartilage and subsequently impair the function of knee joints. This can lead to increased 
pain and decreased functionality. As fragility scores increase, surgeons are apt to deny patients 
knee osteoplasty. Treatment should focus on alleviating symptoms and initiating a therapy that 
will limit tissue degradation. In geriatric patients, PRP treatment was shown to be non-inferior to 
CS injections. PRP produced no adverse effects when given as a single injection with a duration 
of effect of up to six months after a single dose was administered.8 If PRP can eventually become 
covered under plans like Medicare this would provide a much-needed therapy without the 
harmful tissue degradation, often seen in chronic CS injections. 
POTENTIAL VARIATION IN INJECTION SITES 
Providers need to identify the proper injection site(s) for PRP treatment. Traditionally IAI 
is done for all treatments, when treating knee OA. There is potential for better outcomes by 
combining IAI with Intraosseous Injections (IOI), in the medial tibial plateau and the medial 
portion of the femoral epicondyle, thus penetrating deeper layers of the cartilage and asserting 
better therapeutic outcomes. One study found that combining IAI with IOI provided better 
overall and total WOMAC scores and increased duration of effect.4 If feasible, this may become 
a new standard in place of PRP, or the combination of PRP with HA, to decrease pain and 
increase functionality. 
EFFECTIVENESS OF COMBINING HA AND PRP INJECTIONS 
To date, the standard approach of managing the symptoms of knee OA is utilization of a 
monotherapy: either HA or CS, when indicated. Lana and colleagues randomly selected three 
groups which tested the effects of PRP IAI alone, HA IAI alone and the combination of PRP and 
HA IAIs. Each group received three IAI’s of their respective assigned treatment, with two-week 
intervals between each injection. The subjects returned for evaluation at months 1, 3, 6, and 12. 
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They utilized the WOMAC and VAS scores to quantify the efficacy of each of the therapeutic 
agent(s). The PRP group had significantly better outcomes, compared to HA alone, throughout 
all follow-up evaluations in this study. The combination group yielded vastly greater results with 
increased physical function and reduction in pain during months 1 and 3. The Lana study 
suggested that combining the two treatments will provide better outcomes in the first 30 days 
after onset of treatment and continuing treatment with PRP alone will improve quality of life, in 




PRP is a desirable intervention, that may allow health care providers greater options in 
managing patients with knee OA. The ability of a patient to exercise their own judgement to 
select an appropriate therapy for their OA is invaluable to providing the best care. Further 
substantial research and raised awareness for this intervention may lead to insurance providers 
including PRP within their coverage and granting patients a viable and effective means of 
managing their knee OA. Smith and colleagues completed an FDA-sanctioned, randomized 
control, double-blinded, placebo-controlled study in 2016, attempting to provide results that 
would prove the safety and efficacy of utilizing PRP as a monotherapy in treating knee OA.10 
Their results yielded no adverse events and displayed statistically significant improvement in the 
PRP group over the twelve-month study.10 With FDA-sanctioned studies, like this one, it gives 
promise that PRP may become a more available adjunct treatment for knee OA in the near future 
and give providers the option of recommending its use to their patients. 
The limitations of all research studies examined were identified clearly. There are no 
guidelines in any of the studies that suggested a definitive composition to the PRP solution for 
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their injections. This may have skewed the results of their research, either providing too much 
PRP or too small a quantity. There needs to be an established proportion of PRP which, in turn, 
will allow health care providers the ability to begin with an effective dosing and tailor the 
solution with everyone treated. Dosing may also need to be scaled in accordance with the BMI of 
a patient or a patient’s age. Secondly, there was not an agreed upon or established interval for the 
injections, which may have degraded the efficacy of PRP in these studies. Thirdly, there was 
variation amongst the studies in regard to either additions to the PRP injectable solution or 
modifying the PRP solution prior to administration (i.e. Photo-activated PRP).11 Also, the 
injection site(s) have not been clearly established, with one study injecting PRP into the joint- 
space of the knee and within the sub-chondrolar bone.4 The additional injection sites may prove 
to decrease inflammation not only within the knee joint, but also in the peri-articular tissue, 
which may increase its efficacy. Finally, there is an absence of multi-year studies, which may 
provide better insight into the sustained benefits of utilizing PRP for knee OA treatment. 
The strength of these studies lies within the randomized control trial approach. The 
evidence provided was reliable and allowed the results to be trusted. Also, the consistency of 
comparison to other means of management allowed for analysis between traditional interventions 
and the various PRP treatments. 
There is a strong desire by researchers to provide further research for PRP injections in 
the treatment of knee OA. A large scale, longevity study will provide adequate data to inspire 
health care providers and biomedical researchers to consider PRP as a non-inferior method of 
treating chronic OA. Without proper funding and standardization to dosing there will ultimately 




PRP has a great amount of potential to aid in the control of symptoms and potentially 
regrow degenerated cartilage in patients suffering from knee OA. Overall, the research reviewed 
provided adequate evidence to consider PRP non-inferior to HA or CS. Adding PRP to a 
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